Back to Journals » Vascular Health and Risk Management » Volume 11

Fractional flow reserve-guided percutaneous coronary intervention: where to after FAME 2?

Authors van de Hoef T, Meuwissen M, Piek J

Received 31 May 2015

Accepted for publication 26 August 2015

Published 3 December 2015 Volume 2015:11 Pages 613—622


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jaya Mallela

Peer reviewer comments 4

Editor who approved publication: Dr Daniel Duprez

Tim P van de Hoef,1 Martijn Meuwissen,2 Jan J Piek1

1AMC Heartcentre, Academic Medical Center, University of Amsterdam, Amsterdam, 2Amphia Hospital, Breda, the Netherlands

Abstract: Fractional flow reserve (FFR) is a well-validated clinical coronary physiological parameter derived from the measurement of coronary pressures and has drastically changed revascularization decision-making in clinical practice. Nonetheless, it is important to realize that FFR is a coronary pressure-derived estimate of coronary blood flow impairment. It is thereby not the same as direct measures of coronary flow impairment that determine the occurrence of signs and symptoms of myocardial ischemia. This consideration is important, since the FAME 2 study documented a limited discriminatory power of FFR to identify stenoses that require revascularization to prevent adverse events. The physiological difference between FFR and direct measures of coronary flow impairment may well explain the findings in FAME 2. This review aims to address the physiological background of FFR, its ambiguities, and its consequences for the application of FFR in clinical practice, as well as to reinterpret the diagnostic and prognostic characteristics of FFR in the light of the recent FAME 2 trial outcomes.

Keywords: fractional flow reserve, coronary flow, stable ischemic heart disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Personalized medicine and stroke prevention: where are we?

Kim J, Thrift AG, Nelson MR, Bladin CF, Cadilhac DA

Vascular Health and Risk Management 2015, 11:601-611

Published Date: 2 December 2015

Preseason preparation training and endothelial function in elite professional soccer players

Androulakis NE, Koundourakis NE, Nioti E, Spatharaki P, Hatzisymeon D, Miminas I, Alexandrakis MG

Vascular Health and Risk Management 2015, 11:595-599

Published Date: 26 November 2015

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice

Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE

Vascular Health and Risk Management 2015, 11:1-8

Published Date: 17 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010